Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030930 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BLMNASMN1; SMN2ITGAV | |
| SCHEMBL7393007 | 0.99 | ITGB3 (0.47) | ITGB3ITGA2BLMNASMN1; SMN2ITGAV | |
| SCHEMBL7033860 | 0.98 | ITGB3 (0.48) | ITGB3ITGA2BLMNASMN1; SMN2ITGAV | |
| SCHEMBL7036608 | 0.94 | ITGB3 (0.43) | ITGB3ITGA2BLMNASMN1; SMN2ITGAV | |
| SCHEMBL7036103 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BITGAVITGB1ITGA4 | |
| SCHEMBL7036473 | 0.93 | ITGB3 (0.45) | ITGB3ITGA2BITGAVITGB1ITGA4 | |
| SCHEMBL7034232 | 0.92 | ITGB3 (0.40) | ITGB3ITGA2BLMNASMN1; SMN2ITGAV | |
| SCHEMBL7036984 | 0.91 | NAMPT (0.49) | ITGB3ITGA2BLMNAITGAVITGB1 | |
| SCHEMBL7036714 | 0.91 | NAMPT (0.49) | ITGB3ITGA2BLMNAITGAVITGB1 | |
| SCHEMBL7036024 | 0.91 | ITGB3 (0.46) | ITGB3ITGA2BITGAVITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB3 403/4885ITGA2B 573/4885LMNA 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.